

## **Univercells and Unizima announce Hala Audi as Chief Executive Officer of Unizima**

Brussels, Belgium, January 5, 2022

Univercells S.A. (“Univercells”) and Unizima S.A. (“the Company”), announce today the appointment of Hala Audi as Chief Executive Officer of Unizima, a Univercells Company dedicated to delivering facilities, services and expertise to meet local demand for biologics in low-to-middle-income countries. Hala’s appointment will bring the Company to its next level, driven by its mission of delivering life-changing biologics to the people who don’t have access to them.



Hala started her career as a legal expert focusing on commercial litigation and arbitration. Later on, she gained experience in financial management and the governance and funding of public private partnerships, working for the UK Treasury for several years. During her time in the UK Government, she led several teams, working on global health topics with pharmaceutical companies and governments. She delivered difficult and complex system changes and innovations in the construction and public infrastructure sectors, improving staff morale, funding and performance. Over the last year, she was the Chief Executive Officer of The Trinity Challenge, a global charity based in England, launched at the end of 2020.

Hala holds a Masters in Law from the Pantheon-Assas University (Paris), a Master of Laws (LLM) degree from Columbia University Law School (New York), and a Master in Public Administration from the London School of Economics.

**Hugues Bultot, CEO of Univercells Group, commented:** “Univercells has become an incubator for talent, of which the appointment of Hala as the CEO of our newest affiliate, Unizima, is another wonderful example. The Board and I are confident that Hala’s international background of more than 20 years, her cultural sensitivity and expertise, will enable her to lead the expansion of Unizima in 2022 with several exciting projects to come.”

**Hala Audi, addressing her new role as CEO of Unizima, added:** “I am thrilled to join the brilliant team at Univercells Group and Unizima. Local manufacturing and regional supply are essential to solve the challenges of healthcare access. With Unizima and its partners, we have a chance to bring real change on the ground in the next few years and I look forward to working with old and new colleagues across public health, governments and industry to bring the best advances in biologics where they are most needed.”

### ●●● About Unizima ●●●

Unizima, a Univercells company, delivers international biomanufacturing projects from inception to technology transfer and validation. The company brings together all the elements needed to make the project a reality and offer operational support to ensure successful continued operations. The operational support services cover quality control, supply chain and digital oversight. Unizima also devise and implement bioproduction training programs and design and build care centers and diagnostics surveillance centers.

### ●●● About Univercells ●●●

Univercells is a global life sciences company with the mission of making biologics accessible to all. Using our combined expertise in scaling, production, and bioprocessing, Univercells finds new and sustainable ways to widen access to life-changing drugs. Our affiliate companies deploy innovations in infrastructure, drug substance manufacturing, equipment manufacturing, equipment design, training, and on-the-ground health services to drive down costs, shrink manufacturing footprints and meet the needs of the entire health value chain. Headquartered in Jumet (Belgium), Univercells is supported by regional and national investors, as well as international investors active in vaccines and healthcare, such as the Bill and Melinda Gates Foundation, the European Investment Bank and Global Health Investment Fund, among others.

[www.univercells.com](http://www.univercells.com)

### ●●● Disclosure Statement ●●●

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified using forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.